The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
GordonAN, TenerielloM, JanicekMF, et al. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol. 2011;123(3):479–485.
2.
MannelRS, BradyMF, KohnEC, et al. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol. 2011;122(1):89–94.
3.
HoskinsP, VergoteI, CervantesA, et al. Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst. 2010;102(20):1547–1556.
4.
du BoisA, HerrstedtJ, Hardy-BessardAC, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010;28(27):4162–4169.
5.
AravantinosG, FountzilasG, BamiasA, et al. Hellenic Cooperative Oncology Group study. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer. 2008;44(15):2169–2177.
6.
LhomméC, JolyF, WalkerJL, et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol. 2008;26(16):2674–2682.
7.
du BoisA, LückHJ, MeierW, et al. Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95(17):1320–1329.
8.
NeijtJP, EngelholmSA, TuxenMK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18(17):3084–3092.
9.
Pujade-LauraineE, WagnerU, Aavall-LundqvistE, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323–3329.
10.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines – Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. V.2. 2013. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed January 21, 2014.
11.
CheungYW, CradockJC, VishnuvajjalaBR, FloraKP.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm. 1987;44(1):124–130.
Multinational Association of Supportive Care in Cancer. MASCC/ESMO Antiemetic Guidelines 2013.Multinational Association of Supportive Care in Cancer Web site. http://www.mascc.org/antiemetic-guidelines. Accessed January 21, 2014.
15.
GelingO, EichlerHG.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289–1294.
16.
CornelisonTL, ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993;50(2):147–158.
SmithTJ, KhatcheressianJ, LymanGH, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205.
CalvertAH, NewellDR, GumbrellLA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748–1756.
23.
CockcroftDW, GaultMH.Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1): 31–41.
24.
CathomasR, HarleA, MeadGM, Glomerular filtration rate (GFR) in patients with stage I testicular seminoma treated with adjuvant carboplatin: A comparison of six formulae compared to a radioisotope gold standard. J Clin Oncol. 2007;25(18 suppl): abstract15504.
25.
BoumedienF, ArsenaultY, LeTarteN.Impact of weight and creatinine measurements in carboplatin dosing. J Clin Oncol. 2012;30(15 Suppl): abstract e13027.
26.
EkhartC, RodenhuisS, SchellensJHM, BeijnenJH, HuitemaADR. Carboplatin dosing in overweight and obese patients with normal renal function. Does weight matter? Cancer Chemother Pharmacol. 2009;64(1):115–122.
27.
HerringtonJD, TranHT, RiggsMW.Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥27 or cachexia. Cancer Chemother Pharmacol. 2006;57(2):241–247.
28.
DevineBJ.Gentamycin therapy. Drug Intell Clin Pharm. 1974;8:650–655.
29.
KaagD.Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors. Lung Cancer. 2013;79(1):54–58.
30.
HerringtonJD, TranHT, RiggsMW.Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥ 27 or cachexia. Cancer Chemother Pharmacol. 2006;57(2):241–247.
31.
O'CearbhaillR.New guidelines for carboplatin dosing. Gyn Oncol Group Newsletter. 2012;(Spring issue):5–6.
